Trevi Therapeutics (TRVI) Competitors $5.90 -0.08 (-1.40%) As of 07/3/2025 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI vs. HCM, IMVT, OGN, MIRM, AMRX, IBRX, XENE, BHC, GMTX, and APLSShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include HUTCHMED (HCM), Immunovant (IMVT), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Trevi Therapeutics vs. Its Competitors HUTCHMED Immunovant Organon & Co. Mirum Pharmaceuticals Amneal Pharmaceuticals ImmunityBio Xenon Pharmaceuticals Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Trevi Therapeutics (NASDAQ:TRVI) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Does the media prefer TRVI or HCM? In the previous week, Trevi Therapeutics had 6 more articles in the media than HUTCHMED. MarketBeat recorded 10 mentions for Trevi Therapeutics and 4 mentions for HUTCHMED. Trevi Therapeutics' average media sentiment score of 0.47 beat HUTCHMED's score of -0.05 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend TRVI or HCM? Trevi Therapeutics presently has a consensus target price of $20.88, suggesting a potential upside of 254.05%. HUTCHMED has a consensus target price of $19.00, suggesting a potential upside of 19.54%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Trevi Therapeutics is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, TRVI or HCM? Trevi Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Is TRVI or HCM more profitable? HUTCHMED's return on equity of 0.00% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -58.41% -52.52% HUTCHMED N/A N/A N/A Do institutionals and insiders hold more shares of TRVI or HCM? 95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, TRVI or HCM? HUTCHMED has higher revenue and earnings than Trevi Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$47.91M-$0.45-13.10HUTCHMED$630.20M4.40$37.73MN/AN/A SummaryTrevi Therapeutics beats HUTCHMED on 8 of the 13 factors compared between the two stocks. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$701.41M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-13.1021.5627.4020.24Price / SalesN/A274.65418.19125.29Price / CashN/A41.9536.6357.47Price / Book4.547.518.085.67Net Income-$47.91M-$55.05M$3.16B$248.47M7 Day Performance4.91%4.59%2.81%3.29%1 Month Performance-10.40%4.86%3.69%5.18%1 Year Performance120.82%5.82%35.30%21.35% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics3.3093 of 5 stars$5.90-1.4%$20.88+254.1%+120.8%$701.41MN/A-13.1020News CoverageAnalyst ForecastAnalyst RevisionHCMHUTCHMED1.6314 of 5 stars$15.21+2.5%$19.00+24.9%-9.3%$2.65B$630.20M0.001,811IMVTImmunovant1.5647 of 5 stars$15.47-2.1%$38.33+147.8%-35.9%$2.64BN/A-5.65120OGNOrganon & Co.4.8276 of 5 stars$9.82+0.7%$18.00+83.3%-50.4%$2.55B$6.40B3.414,000Trending NewsMIRMMirum Pharmaceuticals3.7125 of 5 stars$50.28-0.1%$65.50+30.3%+47.4%$2.49B$336.89M-31.23140News CoverageAMRXAmneal Pharmaceuticals3.2301 of 5 stars$7.91+1.2%$11.60+46.6%+26.8%$2.48B$2.79B-197.708,100IBRXImmunityBio1.8886 of 5 stars$2.76-3.8%$12.25+343.8%-57.0%$2.44B$14.74M-4.76590Negative NewsGap UpXENEXenon Pharmaceuticals3.2015 of 5 stars$31.49-1.7%$54.82+74.1%-3.9%$2.42B$9.43M-9.75210BHCBausch Health Cos3.1657 of 5 stars$6.11-1.1%$7.42+21.4%-2.8%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+27.8%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.5197 of 5 stars$17.62-0.4%$40.05+127.3%-49.2%$2.21B$775.84M-9.84770Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies HCM Alternatives IMVT Alternatives OGN Alternatives MIRM Alternatives AMRX Alternatives IBRX Alternatives XENE Alternatives BHC Alternatives GMTX Alternatives APLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVI) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRVI Stock Alerts